BEBT 109
Alternative Names: BEBT-109Latest Information Update: 30 Jul 2024
At a glance
- Originator BeBetter Med
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
Most Recent Events
- 23 Jul 2024 BeBetter Med plans a phase II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease, Recurrent, Inoperable/unresectable) in China (PO, capsule) in July 2024 (NCT06514027)
- 25 Sep 2023 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in China (PO) before September 2023 (Be Better medicine pipeline, September 2023)
- 08 Aug 2023 BeBetter Med completes a phase-I trial in Non-small cell lung cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in China (PO) (NCT06001671)